lung failure increases phase iii risk

There's no doubt about it - PI-88 is more likely to fail now it's been established that it doesn't have broad cancer-fighting activity. Anybody that says different doesn't understand the underlying biology.

The market clearly doesn't like this latest development. Expect it to fall further as the full impact sinks in.

Make no mistake - this is a massive blow to PGL's chances of reaching profitability.